Genomic, immunologic, and prognostic associations of TROP2 ( TACSTD2 ) expression in solid tumors
The Oncologist · 04.11.2024 · 29 (11) · e1480-e1491
DOI: 10.1093/oncolo/oyae168 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.07.2024. Verfasst von Dan Morgenstern-Kaplan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, FL …. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cell Adhesion Molecules. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI.
Abstract (Originalsprache)
Background
TROP2 (TACSTD2) expression is associated with decreased overall survival (OS) in some solid tumors, and the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab govitecan has been approved in breast and urothelial carcinomas. We aimed to explore the multi-omic landscape associated with TACSTD2 gene expression in various solid tumors to identify patients most likely to benefit from this approach.
Methods
Breast (N = 11 246), colorectal (N = 15 425), hepatocellular (N = 433), pancreatic (N = 5488), and urothelial (N = 4125) tumors were stratified into quartiles by TACSTD2 gene expression, analyzed by next-generation DNA sequencing, whole transcriptome sequencing, and immunohistochemistry at Caris Life Sciences (Phoenix, AZ). Survival data were obtained from insurance claims, and Kaplan-Meier estimates were calculated for molecularly defined cohorts.
Results
Several pathogenic mutations were associated with TACSTD2-high tumors, including TP53 in breast, colorectal (CRC), pancreatic, and hepatocellular cancers; KRAS in pancreatic and CRC cancers; ARID1A and FGFR3 in urothelial cancer; and CTNNB1 in hepatocellular cancer. TACSTD2-low breast tumors were enriched for copy number amplifications in CCND1 and FGF/R family member genes. TACSTD2 high was generally associated with more immune cell infiltration and greater T-cell inflammation scores. Patients with TACSTD2-high breast, CRC, and pancreatic cancers demonstrated a significantly shorter OS than TACSTD2-low tumors. This was restricted to CRC with microsatellite stable tumors and patients with pancreatic cancer with KRAS-mutant tumors. Patients with breast cancer with TACSTD2-high tumors also experienced significantly worse OS following immune checkpoint inhibitors.
Conclusions
TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, FL 33131, United States.
- Caris Life Sciences, Phoenix, AZ 85040, United States.
- University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, United States.
- Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange, CA 92617, United States.
- Division of Medical Oncology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States.
- Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, United States.
ORCID-Profile: Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris Krause, Jennifer R Ribeiro, Emmanuel S Antonarakis, Emil Lou, Misako Nagasaka, Sandra Algaze, Heinz-Josef Lenz, Balazs Halmos, Dave S B Hoon, Andreas Seeber, Wafik S El-Deiry, Ari M Vanderwalde, Gilberto Lopes
Förderung
- NCI NIH HHS
- NCI
Zitieren
APA
Morgenstern-Kaplan, D., Kareff, S. A., Trabolsi, A., Rodriguez, E., Krause, H., Ribeiro, J. R., Tan, H., Antonarakis, E. S., Lou, E., Nagasaka, M., Algaze, S., Lenz, H. J., Liu, S. V., Halmos, B., Hoon, D. S. B., Seeber, A., Ma, P. C., El-Deiry, W. S., Vanderwalde, A. M., & Lopes, G. (2024). Genomic, immunologic, and prognostic associations of TROP2 ( TACSTD2 ) expression in solid tumors. The Oncologist, 29(11), e1480-e1491. https://doi.org/10.1093/oncolo/oyae168
Vancouver
Morgenstern-Kaplan D, Kareff SA, Trabolsi A, Rodriguez E, Krause H, Ribeiro JR, et al. Genomic, immunologic, and prognostic associations of TROP2 ( TACSTD2 ) expression in solid tumors. The Oncologist. 2024;29(11):e1480-e1491. doi:10.1093/oncolo/oyae168
BibTeX
@article{MorgensternKaplan2024,
author = {Morgenstern-Kaplan, Dan and Kareff, Samuel A and Trabolsi, Asaad and Rodriguez, Estelamari and Krause, Harris and Ribeiro, Jennifer R and Tan, Heng and Antonarakis, Emmanuel S and Lou, Emil and Nagasaka, Misako and Algaze, Sandra and Lenz, Heinz-Josef and Liu, Stephen V and Halmos, Balazs and Hoon, Dave S B and Seeber, Andreas and Ma, Patrick C and El-Deiry, Wafik S and Vanderwalde, Ari M and Lopes, Gilberto},
title = {Genomic, immunologic, and prognostic associations of TROP2 ( TACSTD2 ) expression in solid tumors},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {11},
pages = {e1480--e1491},
doi = {10.1093/oncolo/oyae168}
}
EUVIMED